{"id":"W2152059213","doi":"10.1586/14779072.2014.954551","title":"Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction","year":2014,"lang":"en","type":"review","venue":"Expert Review of Cardiovascular Therapy","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dalhousie University; McMaster University; Thrombosis and Atherosclerosis Research Institute","funders":"","keywords":"PCSK9; Alirocumab; Medicine; Ezetimibe; LDL receptor; Proprotein convertase; Kexin; Familial hypercholesterolemia; Cholesterol; Evolocumab; Internal medicine; Endocrinology; Pharmacology; Lipoprotein","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.004912749,0.001064571,0.01166475,0.0002896651,0.0001304543,0.00003082785,0.0004478884,0.0006845112,0.00006429706],"category_scores_gemma":[0.0002070237,0.0007484335,0.02402863,0.0005580251,0.0001330734,0.00011073,0.00006580038,0.0005463047,0.00004702474],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002936161,"about_ca_system_score_gemma":0.0006659256,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006200282,"about_ca_topic_score_gemma":2.116383e-7,"domain_scores_codex":[0.9931843,0.001093041,0.002193517,0.001211361,0.001686726,0.0006311034],"domain_scores_gemma":[0.9940913,0.00007195874,0.0008134809,0.004085547,0.0005984967,0.0003392246],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002212453,0.00007764136,3.023573e-8,0.2398372,0.008612431,0.000004446204,0.00002360826,1.871821e-7,0.000001989703,0.00001500219,0.004370783,0.7470345],"study_design_scores_gemma":[0.001733105,0.0003828374,4.818253e-7,0.1969644,0.005049924,0.0007600152,0.000005898938,3.962113e-7,0.00006567744,0.000004723221,0.7945192,0.0005134119],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0000013499,0.9828702,0.002989099,0.0001479984,0.001345234,0.01216537,0.00003231159,0.0001161216,0.0003323639],"genre_scores_gemma":[0.000001317805,0.9854102,0.001790725,0.0008061734,0.007015396,0.003981831,0.0004958136,0.0003268934,0.0001716953],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.7901484,"threshold_uncertainty_score":0.9994966,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04405893607552818,"score_gpt":0.3699339682634757,"score_spread":0.3258750321879476,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}